Gerresheimer AG: Can the Recovery Movement Succeed After the Selling Panic? - JPMorgan Sees 120% Price Potential

The Gerresheimer AG has lowered its revenue and margin forecast for the current fiscal year on June 02, 2025. Instead of an expected revenue growth of 3–5%, the company now anticipates only a rise of 1-2%. The adjusted EBITDA margin is expected to be 20%, after previously being forecast at 22%. Gerresheimer cites weaker demand in the cosmetics and liquid medications sectors as the reasons. This announcement resulted in a drop in the stock price of up to 20.8% – the steepest decline since December 2008. Takeover speculation: private equity...